A panel of federal cancer experts says the best-selling cancer drug in the world should no longer be approved to treat breast cancer because it is ineffective and causes dangerous side effects.
The Food and Drug Administration said once before that Avastin, made by Roche, shouldn't be used for breast cancer because it doesn't extend or improve life. The agency granted an unprecedented second hearing after drugmaker Roche protested that conclusion.
The FDA panel voted unanimously to revoke Avastin's FDA approval for breast cancer.
The vote is not binding and FDA's commissioner will make the final decision. The drug is approved for multiple cancers and can be used for breast cancer even if the FDA removes approval. However, many insurers will not pay for the $100,000 drug without the clearance.